Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

Launched by ABBVIE · Oct 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called foscarbidopa/foslevodopa works for adults with advanced Parkinson's disease in a real-world setting. Parkinson's disease is a condition that affects the brain and leads to symptoms like shaking, stiffness, and slow movements. The study will involve about 200 participants across 30 locations in France who are already prescribed this medication by their doctors. The goal is to see how effective the treatment is over a period of up to 12 months.

To be eligible for the trial, participants must have advanced Parkinson's disease and still experience motor problems that their current treatments aren't controlling well enough. They also need to meet specific guidelines for the medication. During the study, participants won’t face extra burdens; they will simply continue with their regular doctor visits as they receive the treatment. It's important to note that participants should not have any health issues that would prevent them from using the medication or have certain cognitive impairments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with advanced Parkinson disease with motor complications insufficiently controlled by current therapy
• • Participants eligible for foscarbidopa / foslevodopa according to French label \& regulation.
• • Treatment initiation decision prior to and independently from study enrolment
• Exclusion Criteria:
• • Participants with any contraindication to foscarbidopa / foslevodopa.
• • Participants with Mini mental state examination (MMSE) score \< 24